Sheba Medical Center to Utilize Sequentify’s InfiniSeq Panel in Study to Detect Clonal Hematopoiesis in Cancer Patients

The Hematology Laboratory, Molecular Hematology Unit, at Sheba Medical Center, Israel’s largest medical center, is conducting a joint study utilizing Sequentify’s InfiniSeqâ„¢ Myeloid Malignancies Panel. This study involves leading clinicians from the Cancer Center Institute, Maccabi Healthcare Services, and Sheba Cancer Research Center, focusing on identifying Clonal Hematopoiesis of Indeterminate Potential (CHIP) in patients previously diagnosed with solid tumors. The results from this study aim to advance personalized medicine in oncology, potentially influencing future patient care protocols.

Sequentify’s myeloid malignancy panel is a highly effective tool for sequencing patients with myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). The straightforward and efficient InfiniSeq library prep protocol is an ideal choice for laboratories aiming to enhance or expand their sequencing capabilities, whether they are upgrading existing workflows or establishing new ones.

Dr. Dan Dominissini, Director of the Diagnostic Division at Sheba Medical Center, commented: “We are thrilled to partner with Sequentify on this study. As one of Israel’s leading research institutes and hospitals, ranked #9 among the world’s best hospitals by Newsweek, Sheba Medical Center is committed to staying at the forefront of diagnostic innovation. Our ultimate goal is to deliver better, faster, and more cost-effective results to our patients.” As part of the study, all patients will undergo sequencing using next-generation sequencing (NGS) technology, with all procedures conducted at the Sheba Medical Center facility to ensure the highest level of accuracy and depth in identifying CHIP.

Sequentify’s InfiniSeq technology reduces sample preparation time to just 3.15 hours, from DNA extraction to sequencing, using a single-tube reaction. It supports full automation and significantly reduces costs. The patent-pending InfiniSeq technology is compatible with most sequencing machines and seamlessly integrates into any lab workflow.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.